Notícias e Atividades da Context Therapeutics

Context Therapeutics é uma empresa listada sob o símbolo CNTX (US).

Veja o organograma con seus 20 executivos principais

Biografias mais buscadas da Context Therapeutics

• Martin Lehr, Chief Executive Officer and Director
• Jennifer Evans Stacey, Director
• Andy Pasternak, Chairman of the Board

Criar um alerta
para seguir os movimentos de executivos da Context Therapeutics.

Context Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Context Therapeutics

• Context Therapeutics to Present at the Jefferies Global Healthcare Conference | Context Therapeutics Inc.
• Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | Context Therapeutics Inc.
• Context Therapeutics Reports First Quarter 2026 Operating and Financial Results | Context Therapeutics Inc.
• Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer | Context Therapeutics Inc.
• Context Therapeutics Reports Full Year 2025 Operating and Financial Results | Context Therapeutics Inc.
• Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 | Context Therapeutics Inc.
• Context Therapeutics to Participate in Upcoming Investor Conferences | Context Therapeutics Inc.
• Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Context Therapeutics Inc.
• Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting | Context Therapeutics Inc.
• Press Releases | Context Therapeutics Inc.
• View more press releases Close

Redes sociais sobre Context Therapeutics

• Context Therapeutics na Wikipedia, Google News e Yahoo Finance
• Context Therapeutics na LinkedIn, X (Twitter) e YouTube